Needham & Company LLC restated their buy rating on shares of Nkarta (NASDAQ:NKTX - Free Report) in a research note released on Wednesday morning, Benzinga reports. Needham & Company LLC currently has a $15.00 price target on the stock.
Several other equities analysts also recently issued reports on the stock. HC Wainwright reduced their price target on shares of Nkarta from $22.00 to $20.00 and set a buy rating for the company in a report on Friday, March 22nd. Raymond James reiterated an outperform rating and issued a $16.00 price objective (up from $13.00) on shares of Nkarta in a research report on Friday, March 22nd. Mizuho decreased their target price on shares of Nkarta from $31.00 to $25.00 and set a buy rating for the company in a research report on Friday, March 22nd. Finally, Canaccord Genuity Group raised their price target on shares of Nkarta from $15.00 to $16.00 and gave the company a buy rating in a research note on Tuesday, March 26th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $17.83.
View Our Latest Research Report on NKTX
Nkarta Trading Down 7.9 %
NKTX traded down $0.69 on Wednesday, hitting $8.06. 1,145,910 shares of the company's stock were exchanged, compared to its average volume of 2,017,536. The stock has a fifty day moving average of $11.09 and a two-hundred day moving average of $6.45. Nkarta has a twelve month low of $1.28 and a twelve month high of $16.24. The firm has a market cap of $398.33 million, a PE ratio of -3.46 and a beta of 0.70.
Nkarta (NASDAQ:NKTX - Get Free Report) last posted its earnings results on Thursday, March 21st. The company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.05. On average, analysts predict that Nkarta will post -2.34 EPS for the current year.
Insider Buying and Selling
In related news, Director Simeon George bought 2,000,000 shares of the stock in a transaction on Wednesday, March 27th. The shares were purchased at an average price of $10.00 per share, with a total value of $20,000,000.00. Following the purchase, the director now owns 1,548,341 shares in the company, valued at $15,483,410. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Simeon George bought 2,000,000 shares of the business's stock in a transaction on Wednesday, March 27th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $20,000,000.00. Following the completion of the transaction, the director now directly owns 1,548,341 shares of the company's stock, valued at approximately $15,483,410. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul J. Hastings sold 9,697 shares of the firm's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total value of $84,751.78. Following the transaction, the chief executive officer now directly owns 390,507 shares of the company's stock, valued at approximately $3,413,031.18. The disclosure for this sale can be found here. Insiders sold 17,392 shares of company stock valued at $165,512 over the last 90 days. 5.60% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Nkarta
Hedge funds have recently made changes to their positions in the business. Sei Investments Co. acquired a new stake in Nkarta during the second quarter valued at approximately $27,000. Natixis acquired a new stake in shares of Nkarta during the 4th quarter valued at $28,000. Advisor Group Holdings Inc. lifted its position in shares of Nkarta by 13,661.1% during the 4th quarter. Advisor Group Holdings Inc. now owns 4,954 shares of the company's stock valued at $29,000 after acquiring an additional 4,918 shares during the last quarter. Bourgeon Capital Management LLC bought a new stake in shares of Nkarta during the 4th quarter worth $30,000. Finally, American Century Companies Inc. grew its holdings in shares of Nkarta by 59.9% in the 3rd quarter. American Century Companies Inc. now owns 21,817 shares of the company's stock worth $30,000 after acquiring an additional 8,177 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company's stock.
Nkarta Company Profile
(
Get Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
See Also
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
